# A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

> **NCT03886220** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 82 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Elagolix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03886220
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-12
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-04-28
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886220, "A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03886220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*